Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings

Genome Medicine

Volumn 1, Issue 4, 2009, Pages

  Katayama, Hiroyuki ^a,b   Paczesny, Sophie ^a,c   Prentice, Ross ^a   Aragaki, Aaron ^a   Faca, Vitor M ^a   Pitteri, Sharon J ^a   Zhang, Qing ^a   Wang, Hong ^a   Silva, Melissa ^a   Kennedy, Jacob ^a   Rossouw, Jacques ^d   Jackson, Rebecca ^e   Hsia, Judith ^f   Chlebowski, Rowan ^g   Manson, JoAnn ^h   Hanash, Samir ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b EISAI CO LTD   (Japan)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f ASTRAZENECA   (United Kingdom)

^g LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; APOLIPOPROTEIN A2; AUTOTAXIN; CATHEPSIN S; CERULOPLASMIN; COMPLEMENT COMPONENT C2; CONJUGATED ESTROGEN; FETUIN; FETUIN A; FOLLISTATIN; GELATINASE A; HYALURONIC ACID; INHIBIN B; KININOGEN; LACTOFERRIN; MACROPHAGE ACTIVATING FACTOR; NOTCH2 RECEPTOR; PLACEBO; PLASMINOGEN; PROTEIN C; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C; TRANSGELIN; TREFOIL PEPTIDE; UBIQUITIN PROTEIN LIGASE E3; VITRONECTIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BONE DEVELOPMENT; CELL ADHESION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; ISOTOPE LABELING; KALLIKREIN KININ SYSTEM; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE; TANDEM MASS SPECTROMETRY; UPREGULATION; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 77950850143     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm47     Document Type: Article

References (69)

1. Marino M, Galluzzo P, Ascenzi P: Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006, 7:497-508.
2. Lobo RA: Estrogen and cardiovascular disease. Ann N Y Acad Sci 1990, 592:286-294; discussion 334-345.
3. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-63.
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
5. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT: Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657.
6. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R: Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006, 166:357-365.
7. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML: Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356:2591-2602.
8. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465-1477.
9. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, Mason E, Brzyski R, Ockene J, Assaf A, LaCroix A, Matthews K, Wallace R: Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med 2005, 165:1976-1986.
10. Prentice RL, Anderson GL: The women's health initiative: lessons learned. Annu Rev Public Health 2008, 29:131-150.
11. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD: Postmenopausal hormone replacement therapy: scientific review. JAMA 2002, 288:872-881.
12. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR: Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006, 166:772-780.
13. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J: Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006, 113:2425-2434.
14. Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM: Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 2005, 93:1108-1116.
15. Ichikawa J, Sumino H, Ichikawa S, Ozaki M: Different effects of transdermal and oral hormone replacement therapy on the reninangiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am J Hypertens 2006, 19:744-749.
16. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA: Effects of estrogen replacement therapy on the reninangiotensin system in postmenopausal women. Circulation 1997, 95:39-45.
17. Andersson I, Aspergren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfusson B: Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988, 297:943-948.
18. Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, Gibson MJ: Effects of hormone replacement therapy on insulinlike growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. Gynecol Endocrinol 2005, 20:176-182.
19. Faca V, Coram M, Phanstiel D, Glukhova V, Zhang Q, Fitzgibbon M, McIntosh M, Hanash S: Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res 2006, 5:2009-2018.
20. Faca V, Pitteri SJ, Newcomb L, Glukhova V, Phanstiel D, Krasnoselsky A, Zhang Q, Struthers J, Wang H, Eng J, Fitzgibbon M, McIntosh M, Hanash S: Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007, 6:3558-3565.
21. Hanash SM, Pitteri SJ, Faca VM: Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579.
22. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM: A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008, 5:e123.
23. Gericke B, Koebnick C, Reimann M, Forterre S, Franz Zunft HJ, Schweigert FJ: Influence of hormone replacement therapy on proteomic pattern in serum of postmenopausal women. Maturitas 2005, 51:334-342.
24. Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, Zhang Q, Newcomb L, Krasnoselesky A, Paczesny S, Choi G, Fitzgibbon M, McIntosh MW, Kemp CJ, Hanash SM: Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 2008, 7:1481-1489.
25. Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, Hussey P, Igra M, Maclean B, Lin CW, Detter A, Fang R, Faca V, Gafken P, Zhang H, Whiteaker J, States D, Hanash S, Paulovich A, McIntosh MW: Computational Proteomics Analysis System (CPAS): an extensible, opensource analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 2006, 5:112-121.
26. Keller A, Nesvizhskii AI, Kolker E, Aebersold R: Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
27. Nesvizhskii AI, Keller A, Kolker E, Aebersold R: A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658.
28. R Development Core Team: R A language and environment for statistical computing. In R Foundation for Statistical Computing. Vienna, Austria; 2007.
29. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
30. Smyth GK: Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor. Edited by Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. New York: Springer; 2005:397-420
31. Benjamini Y, Hochberg Y: Controlling false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 1995, 57:289-300.
32. Nikolsky Y, Ekins S, Nikolskaya T, Bugrim A: A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett 2005, 158:20-29.
33. Jarvinen AK, Autio R, Haapa-Paananen S, Wolf M, Saarela M, Grenman R, Leivo I, Kallioniemi O, Makitie AA, Monni O: Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. Oncogene 2006, 25:6997-7008.
34. Lee TL, Alba D, Baxendale V, Rennert OM, Chan WY: Application of transcriptional and biological network analyses in mouse germ-cell transcriptomes. Genomics 2006, 88:18-33.
35. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
36. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S: Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 2004, 18:1411-1427.
37. Pentecost BT, Teng CT: Lactotransferrin is the major estrogen inducible protein of mouse uterine secretions. J Biol Chem 1987, 262:10134-10139.
38. Teng CT, Walker MP, Bhattacharyya SN, Klapper DG, DiAugustine RP, McLachlan JA: Purification and properties of an oestrogen-stimulated mouse uterine glycoprotein (approx. 70 kDa). Biochem J 1986, 240:413-422.
39. Teng CT: Lactoferrin gene expression and regulation: an overview. Biochem Cell Biol 2002, 80:7-16.
40. Teng CT: Factors regulating lactoferrin gene expression. Biochem Cell Biol 2006, 84:263-267.
41. Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A: Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. Hypertension 1999, 33:108-115.
42. May FE, Westley BR: Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J Pathol 1997, 182:404-413.
43. GeneCards: TFF3 Gene [http://www.genecards.org/cgi-bin/carddisp. pl?gene=TFF3&search=tff3]
44. Gronbaek H, Vestergaard EM, Hey H, Nielsen JN, Nexo E: Serum trefoil factors in patients with inflammatory bowel disease. Digestion 2006, 74:33-39.
45. Vestergaard EM, Poulsen SS, Gronbaek H, Larsen R, Nielsen AM, Ejskjaer K, Clausen JT, Thim L, Nexo E: Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 2002, 48:1689-1695.
46. Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980, 20:353-362.
47. Puistola U, Westerlund A, Kauppila A, Turpeenniemi-Hujanen T: Regulation of 72-kd type IV collagenase-matrix metalloproteinase-2 by estradiol and gonadotropin-releasing hormone agonist in human granulosa-lutein cells. Fertil Steril 1995, 64:81-87.
48. Marin-Castano ME, Elliot SJ, Potier M, Karl M, Striker LJ, Striker GE, Csaky KG, Cousins SW: Regulation of estrogen receptors and MMP2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003, 44:50-59.
49. Qin H, Sun Y, Benveniste EN: The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999, 274:29130-29137.
50. Bian J, Sun Y: Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997, 17:6330-6338.
51. Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki AK, Lynch JK, Baird AE, Johnson KC, Kuller LH, Beresford SA, Rodriguez B: Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials 2007, 2:e28.
52. Fossum S, Hoem NO, Gjonnaess H, Briseid K: Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy. Thromb Res 1999, 93:161-170.
53. McQuillan AM, Eikelboom JW, Hankey GJ, Baker R, Thom J, Staton J, Yi Q, Cole V: Protein Z in ischemic stroke and its etiologic subtypes. Stroke 2003, 34:2415-2419.
54. Galis ZS, Kranzhofer R, Fenton JW 2nd, Libby P: Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:483-489.
55. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA: Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006, 43:943-949.
56. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
57. Wallentin L, Larsson-Cohn U: Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. II. Plasma lipids. Acta Endocrinol 1977, 86:597-607.
58. Fernandez-Real JM, Pugeat M, Grasa M, Broch M, Vendrell J, Brun J, Ricart W: Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: a population study. J Clin Endocrinol Metab 2002, 87:4686-4690.
59. Hashimoto S, Miwa M, Akasofu K, Nishida E: Changes in 40 serum proteins of post-menopausal women. Maturitas 1991, 13:23-33.
60. Iyengar S, Hamman RF, Marshall JA, Majumder PP, Ferrell RE: On the role of vitamin D binding globulin in glucose homeostasis: results from the San Luis Valley Diabetes Study. Genet Epidemiol 1989, 6:691-698.
61. Ikeda Y, Imai Y, Kumagai H, Nosaka T, Morikawa Y, Hisaoka T, Manabe I, Maemura K, Nakaoka T, Imamura T, Miyazono K, Komuro I, Nagai R, Kitamura T: Vasorin, a transforming growth factor betabinding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc Natl Acad Sci USA 2004, 101:10732-10737.
62. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HM, Miller GJ, ten Cate H: The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007, 5:1896-1903.
63. Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E: Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebocontrolled study. Clin Endocrinol (Oxf) 2007, 66:626-631.
64. Taskinen MR, Puolakka J, Pyorala T, Luotola H, Bjaorn M, Kaarianen J, Lahdenpera S, Ehnholm C: Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996, 16:1215-1221.
65. SymAtlas [http://symatlas.gnf.org]
66. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY: Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Bmj 2008, 336:1227-1231.
67. WHI Participant Website [http://www.whi.org]
68. Helgason S, Damber JE, Damber MG, von Schoultz B, Selstam G, Sodergard R: A comparative longitudinal study on sex hormone binding globulin capacity during estrogen replacement therapy. Acta Obstet Gynecol Scand 1982, 61:97-100.
69. Kelver ME, Kaul A, Nowicki B, Findley WE, Hutchens TW, Nagamani M: Estrogen regulation of lactoferrin expression in human endometrium. Am J Reprod Immunol 1996, 36:243-247.